Sugi Predict

Sugi Predict / Compounds / SCHEMBL3474052

SCHEMBL3474052

SCHEMBL3474052

Cc1cn(-n2cnc3c(N)ncnc32)c(=O)[nH]c1=O

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 9/20 0.44
▸ ADORA1 P30542 7/20 0.44
▸ PI4KA P42356 7/20 0.42
▸ PI4K2B Q8TCG2 7/20 0.42
▸ PI4K2A Q9BTU6 7/20 0.42
▸ PI4KB Q9UBF8 7/20 0.42
▸ ADORA2B P29275 3/20 0.41
▸ DTYMK P23919 2/20 0.39
▸ LMNA P02545 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ GSK3B P49841 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ EGFR P00533 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1375443 0.79 XDH (0.54) LMNASMN1; SMN2
SCHEMBL28029278 0.78 ADORA2A (0.46) ADORA2AADORA1PI4KAPI4K2BPI4K2A
SCHEMBL580610 0.76 ADORA2A (0.64) ADORA2AADORA1PI4KAPI4K2BPI4K2A
SCHEMBL2558880 0.76 PI4KA (0.44) ADORA2AADORA1PI4KAPI4K2BPI4K2A
SCHEMBL27773184 0.76 ADORA2A (0.43) ADORA2AADORA1PI4KAPI4K2BPI4K2A
SCHEMBL6839512 0.75 CYP3A4 (0.34) LMNASMN1; SMN2HPGD
SCHEMBL28413958 0.74 ADORA2A (0.62) ADORA2AADORA1PI4KAPI4K2BPI4K2A
SCHEMBL1831279 0.74 XDH (0.50) LMNASMN1; SMN2
SCHEMBL6911224 0.74 ADORA2A (0.41) ADORA2AADORA1PI4KAPI4K2BPI4K2A
SCHEMBL28410735 0.73 ADORA2A (0.60) ADORA2AADORA1PI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226090-A1 Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan IPSEN BIOPHARM LTD. (GB) 2024-07-11 — — US disclosed
CN-114540262-B Method for constructing recombinant microorganism producing L-valine and nucleic acid molecule and biological material used in same 宁夏伊品生物科技股份有限公司 2024-05-03 — — CN disclosed
CN-114539367-B CEY17_RS11900 gene mutant and application thereof in preparation of L-valine 宁夏伊品生物科技股份有限公司 2024-03-01 — — CN disclosed
WO-2023245092-A2 STRESS EDITING OF CAMKIIδ THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-12-21 — — WO disclosed
US-20230088999-A1 Methods For Treating Pancreatic Cancer Using Combination Therapies IPSEN BIOPHARM LTD. (GB) 2023-03-23 — — US disclosed
US-11369597-B2 Methods for treating pancreatic cancer using combination therapies IPSEN BIOPHARM LTD. 2022-06-28 — — US disclosed
CN-114540262-A Method for constructing recombinant microorganism producing L-valine and nucleic acid molecule and biomaterial used therefor 宁夏伊品生物科技股份有限公司 2022-05-27 — — CN disclosed
CN-114539367-A CEY17_ RS11900 gene mutant and application thereof in preparation of L-valine 宁夏伊品生物科技股份有限公司 2022-05-27 — — CN disclosed
CN-114181288-B Process for producing L-valine, gene used therefor and protein encoded by the gene 北京中科伊品生物科技有限公司 2022-05-03 — — CN disclosed
CN-114181288-A Process for producing L-valine, gene used therefor and protein encoded by the gene 北京中科伊品生物科技有限公司 2022-03-15 — — CN disclosed
US-20080108516-A1 SYNTHESIS OF CHEMICAL TAGS INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2008-05-08 — — US disclosed
US-20040043404-A1 Synthesis of chemical tags INTERNATIONAL BUSINESS MACHINES CORPORATION 2004-03-04 — — US disclosed
US-6632612-B2 Forming biocompatible label; provide nucleotide sequences, denature, attach compound which prevents crystalization, monitor denatured nucleotide sequences INTERNATIONAL BUSINESS MACHINES CORP. 2003-10-14 — — US disclosed
US-20010053540-A1 Synthesis of chemical tags SARAF RAVI F (US) 2001-12-20 — — US disclosed
EP-0987336-A2 Synthesis of chemical tags INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2000-03-22 — — EP disclosed
EP-0970102-A1 ANTISENSE INHIBITION OF ANGIOGENIN EXPRESSION THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2000-01-12 — — EP disclosed
US-5844110-A Synthetic triple helix-forming compound precursors UNIVERSITY OF NEBRASKA BOARD OF REGENTS (US) 1998-12-01 — — US disclosed
WO-1998042722-A1 ANTISENSE INHIBITION OF ANGIOGENIN EXPRESSION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1998-10-01 — — WO disclosed
EP-0792283-A1 SYNTHESIS OF PEPTIDE NUCLEIC ACIDS (PNAs) AND ANALOGUES VIA SUBMONOMER APPROACH CHIRON CORPORATION (US) 1997-09-03 — — EP disclosed
WO-1996015143-A1 SYNTHESIS OF PEPTIDE NUCLEIC ACIDS (PNAs) AND ANALOGUES VIA SUBMONOMER APPROACH CHIRON CORPORATION (US) 1996-05-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11369597-B2 Methods for treating pancreatic cancer using combination therapies PNLIP, RNASE1, LPXN ADORA2A 1032/4885ADORA1 4198/4885PI4KA 1066/4885
US-20230088999-A1 Methods For Treating Pancreatic Cancer Using Combination Therapies PNLIP, RNASE1, LPXN ADORA2A 1032/4885ADORA1 4198/4885PI4KA 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.